Small Cap Gainers: CTSO, ALEX, CCXI
3:11 pm Tuesday, July 06th, 2021
Cytosorbents Corp (NASDAQ: CTSO): Received full FDA approval for its Investigational Device Exemption application to conduct the pivotal STAR-T trial on the removal of ticagrelor during cardiothoracic surgery. STAR-T, which is being performed under FDA Breakthrough Designation, is expected to begin enrollment this summer. Shares of CTSO are up 15.65% to $8.50.
Alector Inc (NASDAQ: ALEC) continued strength following co’s announcement of an immuno-neurology collaboration with GlaxoSmithKline (GSK) on Friday. The stock is up another 12% to $39.43. The agreement will have the two companies working together to develop the AL001 and AL101 antibodies.
These antibodies will be used in the treatment of a wide variety of neurodegenerative diseases. A few examples worth noting include frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease, and Alzheimer’s disease.
ChemoCentryx Inc (NASDAQ: CCXI) jumped 7% to $1408 following consultations with the FDA, co filed an amendment to its NDA for avacopan for the treatment of ANCA-associated vasculitis, addressing points raised during the May 6 Advisory Committee meeting; the filing has been determined to constitute a major amendment to the NDA and will result in the setting of a new PDUFA goal date of October 7.
“We appreciate the opportunity to put additional data and information before the Agency, information which we believe addresses many of the issues raised at the Advisory Committee meeting,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “We look forward to continuing discussions with the Agency.”
